| Quarter | Call date | Disclosure | Financial quality | Kept | Missed | |
|---|---|---|---|---|---|---|
| Q3'26 | October 21, 2026 | 10/12 | 2 medium, 1 low flags | 3 | 0 | Call sheet → |
| Q2'26 | July 21, 2026 | 5/12 | 2 high, 5 medium, 1 low flags | 1 | 1 | Call sheet → |
| Q1'26 | April 21, 2026 | 9/12 | 1 medium, 5 low flags | 3 | 1 | Call sheet → |
| Q4'25 | January 28, 2026 | 10/12 | 3 medium, 4 low flags | 6 | 0 | Call sheet → |
| Marked | Status | Promise |
|---|---|---|
| Q3'26 | Pending | Bioprocessing consumable push-outs 'highly unlikely' not to return, expected to ship in 2027 Expected shipment period is 2027, which has not started. Absence of recapture in Q3 2026 is not a missed commitment. |
| Q3'26 | Delivered | StatLab acquisition expected to close by the end of 2026 StatLab closed in early Q4, within the year-end deadline. |
| Q3'26 | Pending | FY2026 adjusted diluted EPS guidance of $8.45-$8.60 Fiscal year not yet complete; guidance was raised to $8.57-$8.62 this quarter, a revision upward, not a final delivery verdict. |
| Q3'26 | Exceeded | Q3 2026 adjusted operating profit margin of approximately 26.5% Actual Q3 adjusted operating margin was 29.0%, well above guide, partly aided by a tariff refund. |
| Q3'26 | Exceeded | Q3 2026 core revenue growth of approximately 2%-3%, including approximately 5% excluding respiratory revenue Actual Q3 core revenue growth was 3% (top of range) and ex-respiratory core growth came in at 5.5%, above the ~5% guided. |
| Q2'26 | Pending | Respiratory revenue of $1.6-1.7B for full year Narrowed to ~$1.6B or below |
| Q2'26 | Pending | China diagnostics headwinds of $75-100M Maintaining guidance, volumes slightly better than expected |
| Q2'26 | Pending | Life Sciences consumables to be slightly down for full year Now tracking to 'slightly positive' given Q2 strength |
| Q2'26 | Exceeded | Masimo to close later this year Closed in early June, ahead of schedule |
| Q2'26 | Missed | Bioprocessing to grow high single digits for full year Quietly cut to 'mid-single digits' despite claiming healthy demand |
| Q2'26 | Pending | Exit Q4 at mid-single digit core revenue growth rate Reiterated but now requires bigger Q4 acceleration given Q2 shortfall |
| Q1'26 | Delivered | China diagnostics policy headwinds playing out as expected $75-100M headwind assumption validated by Q1 performance |
| Q1'26 | Delivered | Life Sciences modest improvement in end markets Saw better than expected performance in consumables and China acceleration |
| Q1'26 | Pending | 3-6% core revenue growth for full year 2026 Q1 at 0.5% but maintained full-year guide. Need acceleration through year |
| Q1'26 | Missed | Respiratory revenue of approximately $1.8B for full year 2026 Lowered to $1.6-1.7B due to lighter than normal Q1 season. Recalibrating endemic assumptions |
| Q1'26 | Pending | Equipment revenue improving to approximately flat for 2026 Orders support this but equipment declined modestly in Q1. 30%+ order growth gives confidence |
| Q1'26 | Delivered | Bioprocessing high single-digit growth for full year 2026 Q1 showed 7% growth, consistent with high single-digit promise |
| Q4'25 | Delivered | More than 100 basis points margin expansion in 2026 Confirmed with specific $250M cost savings quantification |
| Q4'25 | Pending | Diagnostics acceleration past China VBP headwinds Still working through but expect improvement in 2026 |
| Q4'25 | Delivered | Life Sciences flat growth assumption 0.5% growth meets flat expectation despite pharma recovery |
| Q4'25 | Delivered | High single-digit bioprocessing growth continuing Maintained momentum with equipment inflection providing upside |
| Q4'25 | Delivered | 3% to 6% core growth framework for 2026 Converted framework into formal guidance range |
| Q4'25 | Delivered | Cautious equipment spending through remainder of 2025 Equipment turned positive in Q4 but remained cautious through most of year as guided |
| Q4'25 | Exceeded | Respiratory revenue approximately $1.7 billion in 2026 Revised upward to $1.8B but reflects reassessment of endemic baseline, not seasonal strength |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.